A password will be e-mailed to you.

Adding to an already robust cultivation profile, Invictus MD Strategies (IMHCA)(IVITF) announced last week that its wholly-owned Acreage Pharms unit had acquired 23 new strains of cannabis, a critical step in broadening the company’s strain variety as it approaches full capacity production later this year. The addition of the 23 new cannabis strains to Acreage Pharms’ portfolio expands the company’s already innovative and ambitious genetics breeding program, improving its ability to offer a variety of strains that fully reflect the genetic diversity of cannabis, including its many health-enhancing properties, for medical and recreational use. Invictus made some remarkable strides in 2017, positioning the company to capitalize on the significant market opportunity of the burgeoning legalized Cannabis market. Those steps paved the way for 2018 to be the most promising year yet for Invictus. The company “The acquisition of these strains broadens Acreage Pharms strain variety in preparation for the recreational market,” said Dan Kriznic, Chairman and CEO of Invictus, in the announcement. “The timing is ideal, as our Phase 2 expansion includes 11 new flowering rooms, all of which will be needed to accommodate this welcome and dramatic expansion of strains.” How Invictus Positioned Itself at the Forefront of the Legalized Cannabis Market

thumbnail courtesy of equities.com

No more articles